CN1898370A - 油脂组合物 - Google Patents
油脂组合物 Download PDFInfo
- Publication number
- CN1898370A CN1898370A CNA2004800385954A CN200480038595A CN1898370A CN 1898370 A CN1898370 A CN 1898370A CN A2004800385954 A CNA2004800385954 A CN A2004800385954A CN 200480038595 A CN200480038595 A CN 200480038595A CN 1898370 A CN1898370 A CN 1898370A
- Authority
- CN
- China
- Prior art keywords
- acid
- alpha
- fat
- fatty acid
- oil composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 122
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 62
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 60
- 235000019197 fats Nutrition 0.000 claims abstract description 46
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 43
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 37
- 229930195729 fatty acid Natural products 0.000 claims abstract description 37
- 239000000194 fatty acid Substances 0.000 claims abstract description 37
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 35
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 24
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 23
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 23
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 claims description 42
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 41
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 40
- 230000000694 effects Effects 0.000 claims description 25
- HXWJFEZDFPRLBG-UHFFFAOYSA-N Timnodonic acid Natural products CCCC=CC=CCC=CCC=CCC=CCCCC(O)=O HXWJFEZDFPRLBG-UHFFFAOYSA-N 0.000 claims description 22
- PIFPCDRPHCQLSJ-WYIJOVFWSA-N 4,8,12,15,19-Docosapentaenoic acid Chemical compound CC\C=C\CC\C=C\C\C=C\CC\C=C\CC\C=C\CCC(O)=O PIFPCDRPHCQLSJ-WYIJOVFWSA-N 0.000 claims description 21
- PIFPCDRPHCQLSJ-UHFFFAOYSA-N Clupanodonic acid Natural products CCC=CCCC=CCC=CCCC=CCCC=CCCC(O)=O PIFPCDRPHCQLSJ-UHFFFAOYSA-N 0.000 claims description 20
- 235000021290 n-3 DPA Nutrition 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 15
- 239000004519 grease Substances 0.000 claims description 14
- 244000124853 Perilla frutescens Species 0.000 claims description 11
- 235000005911 diet Nutrition 0.000 claims description 9
- 230000037213 diet Effects 0.000 claims description 9
- 230000004438 eyesight Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 6
- 235000004347 Perilla Nutrition 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 5
- 239000012190 activator Substances 0.000 claims description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 5
- 235000005493 rutin Nutrition 0.000 claims description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 5
- 229960004555 rutoside Drugs 0.000 claims description 5
- 241000251468 Actinopterygii Species 0.000 claims description 4
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 4
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 4
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 4
- 235000021014 blueberries Nutrition 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- 235000011201 Ginkgo Nutrition 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 3
- 241000180649 Panax notoginseng Species 0.000 claims description 3
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 3
- 240000002834 Paulownia tomentosa Species 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000004426 flaxseed Nutrition 0.000 claims description 3
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- 235000009697 arginine Nutrition 0.000 claims description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 229940067626 phosphatidylinositols Drugs 0.000 claims description 2
- 235000015170 shellfish Nutrition 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract description 8
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 abstract 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract 1
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 51
- 235000019198 oils Nutrition 0.000 description 51
- 230000006870 function Effects 0.000 description 23
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 13
- 229960004232 linoleic acid Drugs 0.000 description 13
- 235000013305 food Nutrition 0.000 description 12
- 239000002775 capsule Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 239000007901 soft capsule Substances 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- -1 krill Natural products 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000010496 thistle oil Substances 0.000 description 4
- 241000239366 Euphausiacea Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000002383 tung oil Substances 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 241000555825 Clupeidae Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000237509 Patinopecten sp. Species 0.000 description 2
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 2
- 244000000231 Sesamum indicum Species 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000014134 echinacea Nutrition 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- 235000020637 scallop Nutrition 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- BZFBDUQOBQHBSZ-DLCQERRASA-N (3s,8r,9s,10r,13s,14s,17s)-17-[3-(dimethylamino)propyl-methylamino]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol;dihydrochloride Chemical compound Cl.Cl.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](N(C)CCCN(C)C)[C@@]1(C)CC2 BZFBDUQOBQHBSZ-DLCQERRASA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000906543 Actaea racemosa Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 240000004530 Echinacea purpurea Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- 241000932075 Priacanthus hamrur Species 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 241001312569 Ribes nigrum Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000238371 Sepiidae Species 0.000 description 1
- 244000145469 Vernonia anthelmintica Species 0.000 description 1
- 235000013018 Vernonia anthelmintica Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229940106134 krill oil Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000001343 mnemonic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B11/00—Recovery or refining of other fatty substances, e.g. lanolin or waxes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fats And Perfumes (AREA)
Abstract
本发明涉及一种n-3系列多元不饱和脂肪酸在体内的吸收率高、向组织转移的比例高,可充分发挥该脂肪酸所具有的药理作用的组合物。该油脂组合物含有以选自二十二碳六烯酸、二十二碳五烯酸和二十碳五烯酸的n-3系列多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂。
Description
技术领域
本发明涉及含有以二十二碳六烯酸等n-3系列多元不饱和脂肪酸为结构脂肪酸的磷脂、α-亚麻酸和/或含α-亚麻酸的油脂的油脂组合物。
背景技术
在鱼油、海豹等海洋兽类油等中,含有大量的二十二碳六烯酸(DHA)、二十二碳五烯酸(DPA)、二十碳五烯酸(EPA)。它们都是n-3系列多元不饱和脂肪酸,作为共同的药理作用,报告有减少中性脂肪的作用、抑制血小板凝集的作用。有报告表明二十二碳六烯酸还具有提高记忆学习能力、提高视力、抗炎症作用、降低血浆胆甾醇等药理作用,二十二碳五烯酸具有预防动脉硬化、改善癌症或风湿病等药理作用,二十碳五烯酸具有降低血液粘度、增加HDL等药理作用,因此是受人瞩目的有前景的健康食品材料。
但是,由于这些脂肪酸向组织的转移性不充分,因此,存在着即使将其吸收也达不到预期效果的问题,所以,人们为解决该问题,对二十二碳六烯酸和/或二十碳五烯酸向血液中的转移性高的组合物(参照例如专利文献1)等、以及促进该脂肪酸在体内的吸收进行了研究。
另外,有报告表明,二十二碳六烯酸、二十二碳五烯酸等n-3系列多元不饱和脂肪酸在天然状态下,大多以甘油三酯(鱼油)或甘油磷酸脂(磷虾油)的形态存在,甘油磷酸脂型物质与甘油三酯型相比,摄入时的吸收性高,且对于多元不饱和脂肪酸本身的氧化变质的稳定性高,所以近年来被用作食品等的原材料(例如参照专利文献2、非专利文献1)。由于这类甘油磷酸脂型多元不饱和脂肪酸在常温下呈固态或半固态,不能直接用于食品等用途,所以在特意溶于亚油酸(linoleicacid)的状态下使用,即使如此,其体内的吸收性、向组织的转移性仍被认为不够充分。而且最近人们清楚了解大量摄取亚油酸成为心脏病、癌症、变应性过敏症等的主要危险因素,而盼望效果更好、安全性更高的油状组合物的出现。
另一方面,亚麻仁油、紫苏油、白苏油、桐油中含有大量α-亚麻酸,这是一种在9、12、15位具有顺式双键的直链脂肪酸,已知对预防过敏、预防高血压、预防乳腺癌、提高学习能力、提高视力很有效果(例如参照专利文献3)。但迄今为止,由甘油磷酸脂型二十二碳六烯酸等与α-亚麻酸或含有该亚麻酸的油脂配合而成的组合物尚未为人所知。
专利文献1:日本专利特开2001-120189号公报
专利文献2:日本专利特开2001-186898号公报
专利文献3:日本专利特开平06-70717号公报
非专利文献1:金田辉之、另一名,“DNAは長寿に寄与できるか”食品と開発,1999年,Vol.34,No.8,p.41-43
发明内容
本发明的目的在于提供一种提高n-3系列多元不饱和脂肪酸在体内的吸收率、向组织的转移率,可充分发挥该脂肪酸所具有的药理作用的组合物。
本发明人等鉴于上述实际情况,经过深入研究,结果发现,作为n-3系列多元不饱和脂肪酸的供给源,使用将该多元不饱和脂肪酸作为结构脂肪酸的磷脂,将其中配合α-亚麻酸和/或含α-亚麻酸的油脂而生成油脂组合物时,能大幅度提高该多元不饱和脂肪酸在体内的吸收,并能使其适度地向有需求的组织转移,充分发挥改善中枢神经功能的作用、改善循环功能的作用等n-3系列多元不饱和脂肪酸所具有的药理作用。
即,本发明提供一种油脂组合物,其含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的n-3系列多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂。
另外,本发明提供一种含有上述油脂组合物的饮食品。
本发明还提供一种含有上述油脂组合物的医药品。
本发明还提供一种中枢神经功能改善剂,其含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂。
本发明还提供一种循环功能改善剂,其含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂。
本发明还提供一种改善中枢神经功能的方法,其特征在于,给药含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂的油脂组合物。
本发明还提供一种改善循环功能的方法,其特征在于,给药含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂的油脂组合物。
本发明还提供一种用于制造中枢神经功能改善剂的油脂组合物的应用,该油脂组合物含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂的。
另外,本发明提供一种用于制备循环功能改善剂的油脂组合物的应用,该油脂组合物含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂的。
本发明的油脂组合物,由于n-3系列多元不饱和脂肪酸在体内的吸收率以及向组织转移的比例高,可充分发挥该脂肪酸所具有的药理作用,因此可有效用作有效发挥改善中枢神经功能作用、改善视力作用、改善循环功能作用等的饮食品或医药品。
具体实施方式
本发明的磷脂为以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的n-3系列多元不饱和脂肪酸为结构脂肪酸存在的磷脂。
在本发明中,“以n-3系列多元不饱和脂肪酸为结构脂肪酸”是指以n-3系列多元不饱和脂肪酸残基为酰基存在,既可以是结构脂肪酸的一部分为n-3系列多元不饱和脂肪酸,也可以是结构脂肪酸的全部为n-3系列多元不饱和脂肪酸。
以该n-3系列多元不饱和脂肪酸为结构脂肪酸的磷脂既可以是化学合成品,也可以是从磷虾、乌贼、扇贝等天然产物中提取出的提取物,还可以是从天然产物中提取出来、由化学处理或酶处理等得到的产物(日本特开2001-186898号公报,日本特开平9-121879号公报等)。磷脂的种类可举出卵磷脂、磷脂酰丝氨酸、磷脂酰肌醇、磷脂酰乙醇胺、磷脂酸、磷脂酰心磷脂(phosphatidyl cardiolipin)等,优选为卵磷脂、磷脂酰丝氨酸。
特别优选为以二十二碳六烯酸为结构脂肪酸的卵磷脂(PC-DHA)、以二十碳五烯酸为结构脂肪酸的卵磷脂(PC-EPA)、以二十二碳六烯酸为结构脂肪酸的磷脂酰丝氨酸(PS-DHA)、以二十碳五烯酸为结构脂肪酸的磷脂酰丝氨酸(PS-EPA)。
在本发明油脂组合物中,这些磷脂可以单独使用,也可2种以上混合使用。
本发明中的α-亚麻酸除可采用化学合成品之外,还可以是从菜籽、向日葵、大豆、亚麻仁(linseed)、紫苏(perilla)、白苏(egoma)、桐(tung)等天然产物中提取或精制而得到的产物。
另外,含有α-亚麻酸的油脂可举出菜籽油、葵花油、大豆油、芥花籽油(Canola oil)、亚麻仁油、紫苏油、白苏油、桐油等,也可2种以上混合使用。优选为亚麻仁油、紫苏油、白苏油、桐油中的1种或2种以上,进一步优选为亚麻仁油。为提高磷脂中的二十二碳六烯酸、二十二碳五烯酸或二十碳五烯酸在生物体内的吸收能力,该油脂优选为相对于1重量份的α-亚麻酸含有0~0.7重量份、优选为0~0.5重量份、更优选为0~0.25重量份、进一步优选为0~0.1重量份的亚油酸,特别优选为完全不含亚油酸。
在本发明油脂组合物中,磷脂与α-亚麻酸和/或含有α-亚麻酸的油脂的重量比优选为相对于1重量份磷脂,α-亚麻酸和/或含有α-亚麻酸的油脂的含量为0.1~20重量份、优选为0.25~10重量份、更优选为0.5~4重量份,特别优选为0.75~2重量份。
在本发明的油脂组合物中,可配合从鱼类贝类中提取出的油,例如从金枪鱼、沙丁鱼、鰤鱼、鰤鱼幼鱼、鲹科鱼、鲑鱼籽、磷虾、扇贝等提取出的油,还可配合二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸等来源于天然产物或化学合成的其它油,优选为易于调制的从金枪鱼、沙丁鱼、磷虾中提取出的油。
另外,在本发明油脂组合物中,还可添加用于进一步提高该油脂组合物所具有的改善中枢神经功能的作用、改善视力的作用、改善循环功能的作用的化合物或生药。在本发明中,用于进一步提高中枢神经功能改善作用的化合物或生药可以举出例如五加科植物(人参、田七人参等)、刺五加、精氨酸、银杏叶、大豆、肉毒碱等,用于进一步提高视力改善作用的化合物或生药可以举出例如越桔、蓝莓、覆盆子、芦丁、黑醋栗等,用于进一步提高循环功能改善作用的化合物或生药可以举出例如柠檬酸、芝麻、发芽芝麻、芦丁(rutin)、大蒜、洋葱、纳豆、紫锥菊(echinacea)、黑升麻(black cohosh)等,可适当添加其中的1种或2种以上。特别优选的生药可举出人参、田七人参、刺五加、越桔、精氨酸、银杏叶、芦丁。
本发明的油脂组合物,还可添加通常情况下可采用的抗氧化剂。这类抗氧化剂可举出例如维生素C、维生素E、儿茶素、虾青素、芝麻素、多酚等,可使用其中的1种或2种以上。优选为维生素E。
本发明的油脂组合物可通过将以n-3系列多元不饱和脂肪酸为结构脂肪酸的磷脂,和α-亚麻酸和/或含α-亚麻酸的油脂,以及上述各种成分一边搅拌一边溶解调制而成。
如后述实施例所示,如此得到的本发明的油脂组合物与溶解在亚油酸中的PS-DHA、PC-DHA等相比,体内吸收率和向组织的转移率高,能发挥出优异的改善中枢神经功能的作用、改善循环功能的作用等。
因此,本发明的油脂组合物可有效用作发挥改善中枢神经功能作用、改善循环功能作用等的医药品或饮食品。另外,饮料食品可制成发挥改善中枢神经功能作用、改善视力作用、改善循环功能作用等的患者用食品、特定保健用食品等。还可制成在制品、包装或商品目录等中根据需要附带有该制品是用于改善中枢神经功能作用、改善视力作用、改善循环功能作用的饮食品这一意思表示的食品。
将本发明的油脂组合物用作饮食品时,其形态可采用固态食品、凝胶态食品、液态食品等所谓的饮料或食品形态,可举出例如液体、粉末、胶囊、颗粒、片剂等形态,优选为易加工的胶囊。这类饮食品可根据常用方法进行加工。
调制胶囊时,作为填充内容物除了本发明的油脂组合物之外,还可使用食品中常用的填料、赋形剂、结合剂、崩解剂、稳定剂、分散剂、着色剂、香味剂、长链不饱和脂肪酸、中长链脂肪酸甘油酯类、聚乙二醇类、甘油脂肪酸酯类等表面活性剂等进行调制。胶囊制剂的剂型可举出软胶囊、硬胶囊、微胶囊等,优选为易于调制的软胶囊。另外,对于以明胶构成的胶囊制剂,为了防止其不溶,优选在填充内容物中添加大豆卵磷脂或卵黄卵磷脂。
调制软胶囊时,可采用使用例如旋转式全自动软胶囊成型机冲压法,在两片明胶片之间填入填充内容物、用模具从两面压缩冲压的平板法,或采用双喷嘴的滴下法(无缝胶囊等)等进行调制。
另外,当本发明的油脂组合物制成医药品时,可添加制剂上允许的载体,采用常用方法调制。医药品的剂型没有特定限制,例如可举出胶囊、锭剂、丸剂、片剂、散剂、颗粒剂等,优选为易于制成制剂的胶囊。
本发明的中枢神经功能改善剂、循环功能改善剂等医药或饮食品的给药量(有效摄入量)按照每天的DHA摄入量计,优选为0.5~25mg/kg体重、更优选为1~15mg/kg体重、特别优选为2~8mg/kg体重。
下面,根据实施例说明本发明,但本发明并不限于此。
实施例
实施例1
刚断奶后的ICR系雌性小老鼠(3周龄),用含n-3系列多元不饱和脂肪酸的饲料(约3%的α-亚麻酸/总脂质)或含n-3系列多元不饱和脂肪酸不足的饲料(约0.04%的α-亚麻酸/总脂质)饲养,分别得到正常发育的小老鼠和或n-3系列多元不饱和脂肪酸摄入不足的小老鼠。在8周龄时,使之与9周龄的ICR系雄性小老鼠交配,得到第2代小老鼠。所得第2代小老鼠在其出生2天以内,每1只母老鼠带仔10只,此后也用同样的饲料饲养。在第2代7周龄时,调制PS-DHA(以二十二碳五烯酸为结构脂肪酸的磷脂酰丝氨酸)溶于亚油酸(红花油:相对于1份α-亚麻酸,亚油酸比例为780份)的油脂组合物以及PS-DHA溶于α-亚麻酸(亚麻仁油:相对于1份α-亚麻酸,亚油酸比例为0.46份)的油脂组合物,按照1天的摄入量计分别为DHA 6mg,PS 9mg,一星期后,测量血清中的DHA和脑内的DHA。结果如表1所示。
表1
相对于全部脂肪酸DHA含量(%):n=5
实验组 | PS-DHA+亚油酸(红花油) | PS-DHA+α-亚麻酸(亚麻仁油) |
血清 | 4.24±0.10 | 6.60±0.23 |
脑内 | 5.20±0.17 | 6.03±0.12 |
由表1可知,将磷脂的酰基为DHA的结合体溶于α-亚麻酸的实验组无论是在血清中还是在脑内,其DHA含量均高于亚油酸实验组。这表明:通过将PS-DHA溶于α-亚麻酸,以DHA不足为初始状态,迅速吸收DHA,向组织中转移。最终,相对于脑组织中全部脂肪酸,DHA的含量约为16%。并可推测:尽早趋近这一数值,将会对中枢神经功能有明显的有益作用。
实施例2
刚断奶的ICR系雌性小老鼠(3周龄),用含n-3系列多元不饱和脂肪酸的饲料(约3%α-亚麻酸/总脂质)或含n-3系列多元不饱和脂肪酸不足的饲料(约0.04%α-亚麻酸/总脂质)饲养,分别得到正常发育的小老鼠和或n-3系列多元不饱和脂肪酸摄入不足的小老鼠。在8周龄时,使之与9周龄的ICR系雄性小老鼠交配,得到第2代小老鼠。所得第2代小老鼠在其出生2天以内,每1只母老鼠带仔10只,此后也用同样的饲料饲养。在第2代7周龄时,每天1次经口服用按照实施例1调制的待检药物,从开始服用的第2.5周之后开始,到第4周为止的11天内,实施避暗法(step through)型学习试验,结果如表2所示。
(避暗法型学习试验)
采用具有能承受电冲击的具有暗室和明室的装置(小原医科产业,Model PA-M1)。将老鼠放入明室后,根据习性向暗室移动,但由于暗室底部铺有通电格栅,格栅被施加36V的电冲击,因此小鼠为逃避电击而迅速返回明室。受到一次电击后的老鼠会返回窝内(home cage),以避免在此段期间(session)再次受到电击。从第二天开始,在10天内每天重复同样的操作,测量时间最长为5分钟,以10天内的失败次数为指标对各组进行评价。
表2
n-3系列多元不饱和脂肪酸摄入不足的老鼠在10天内的失败次数(次)
PS-DHA+亚油酸(红花油) | PS-DHA+α-亚麻酸(亚麻仁油) |
1.00±0.26 | 0.86±0.14 |
由表2可知,与使用含有大量亚油酸的红花油的情况相比,使用含有大量α-亚麻酸的亚麻仁油时,10天内失败次数减少。如果学习效果仅有少许差异时,但当反复施行时,复合效果就使得这种差异变大,而表2中的差异就能充分证明α-亚麻酸的有效性。
实施例3PC-DHA的实施例
与实施例1和实施例2一样地得到n-3系列多元不饱和脂肪酸摄入不足的小老鼠的第2代ICR系小老鼠。在第2代的雄性老鼠10~13周龄时,调制PC-DHA溶于亚油酸的油脂组合物以及PC-DHA溶于α-亚麻酸的油脂组合物,按照1天的摄入量计分别为DHA 11mg,PC11mg,测量2小时后的血浆DHA以及连续服用4天后第5天的血浆及红细胞内的DHA。结果如表3所示。
表3
相对于全部脂肪酸DHA含量(%):n=5
实验组 | PC-DHA+亚油酸(红花油) | PC-DHA+α-亚麻酸(亚麻仁油) |
2小时后的血浆 | 2.42±0.13 | 3.43±0.40 |
第5日的血浆 | 6.03±0.56 | 7.22±0.25 |
第5日的红血球 | 2.37±0.09 | 2.78±0.20 |
由表3可知,与实施例1一样,对于PC-DHA同样表现出当将PC-DHA溶于α-亚麻酸,以DHA不足为初始状态,迅速吸收DHA,向组织中转移的结果。已知,PC-DHA可特异地向红细胞转移,最终,相对于红细胞中的全部脂肪酸,DHA含量约为6%,并可推测:尽早趋近这一数值,将会对增加红细胞流动性等循环功能有明显的有益作用。
实施例4软胶囊制剂的调制
(1)用高速搅拌器(10000rpm,5分钟)搅拌表4所示各成分,使之均匀,调制填充内容物。
表4
成分 | A-1(%) | A-2(%) |
亚麻仁油 | 50 | 50 |
PC-DHA | 40 | - |
PS-DHA | - | 40 |
大豆卵磷脂 | 10 | 10 |
(2)将含有明胶45质量%、甘油15质量%以及水40质量%的明胶溶液在80℃下溶解、脱泡,然后静置约10小时,采用旋转式软胶囊填充机(Oval 6型),分别填充按照(1)调制的填充内容物(A-1和A-2)各360mg。胶囊填充完毕后,在温度27℃、湿度50%以下的条件下使膜干燥至含水量为8%,制造软胶囊制剂。将这些软胶囊在温度40℃、湿度75%的条件下保存1周,内容物无变化,胶囊在崩解性方面也没有问题。
Claims (15)
1.一种油脂组合物,其特征在于:
含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的n-3系列多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含有α-亚麻酸的油脂。
2.如权利要求1所述的油脂组合物,其特征在于:
所述磷脂为卵磷脂、磷脂酰丝氨酸、磷脂酰乙醇胺、磷脂酰肌醇、磷脂酸或磷脂酰心磷脂。
3.如权利要求1或2所述的油脂组合物,其特征在于:
所述含有α-亚麻酸的油脂来源于选自亚麻仁、紫苏、白苏、桐的植物。
4.如权利要求1~3中任一项所述的油脂组合物,其特征在于:
含有从鱼类贝类中提取出的油。
5.如权利要求1~4中任一项所述的油脂组合物,其特征在于:
含有具备改善中枢神经功能的作用、改善视力的作用、改善循环功能的作用的化合物或生药。
6.如权利要求5所述的油脂组合物,其特征在于:
所述化合物或生药选自人参、田七人参、刺五加、越桔、精氨酸、银杏叶、芦丁。
7.含有如权利要求1~6中任一项所述的油脂组合物的饮食品。
8.如权利要求7所述的饮食品,其特征在于:
带有用于改善中枢神经功能、改善视力、改善循环功能的意思表示。
9.含有如权利要求1~6中任一项所述油脂组合物的医药品。
10.一种中枢神经功能改善剂,其特征在于:
含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂。
11.一种循环功能改善剂,其特征在于:
含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂。
12.一种改善中枢神经功能的方法,其特征在于:
给药含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂的油脂组合物。
13.一种改善循环功能的方法,其特征在于:
给药含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂的油脂组合物。
14.一种用于制造中枢神经功能改善剂的油脂组合物的应用,其特征在于:所述油脂组合物含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂。
15.一种用于制造循环功能改善剂的油脂组合物的应用,其特征在于:所述油脂组合物含有以选自二十二碳六烯酸、二十二碳五烯酸、二十碳五烯酸的多元不饱和脂肪酸为结构脂肪酸的磷脂的1种或2种以上,以及α-亚麻酸和/或含α-亚麻酸的油脂。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003424791 | 2003-12-22 | ||
JP424791/2003 | 2003-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1898370A true CN1898370A (zh) | 2007-01-17 |
Family
ID=34708795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004800385954A Pending CN1898370A (zh) | 2003-12-22 | 2004-12-21 | 油脂组合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070122452A1 (zh) |
EP (1) | EP1698685A4 (zh) |
JP (1) | JPWO2005061684A1 (zh) |
KR (1) | KR20060127865A (zh) |
CN (1) | CN1898370A (zh) |
CA (1) | CA2549429A1 (zh) |
WO (1) | WO2005061684A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103947770B (zh) * | 2014-05-16 | 2016-03-09 | 普洱联众生物资源开发有限公司 | 一种有利于视力的天然植物油 |
CN105412227A (zh) * | 2015-12-02 | 2016-03-23 | 北京世纪合辉医药科技股份有限公司 | 一种不饱和脂肪酸膳食补充剂及其制备方法 |
CN105962359A (zh) * | 2016-05-10 | 2016-09-28 | 中国农业科学院油料作物研究所 | 一种具有辅助改善记忆功能的组合物 |
CN110946099A (zh) * | 2019-12-13 | 2020-04-03 | 宁波大学 | 一种提高双壳贝类苗种繁育产量的方法 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2549429A1 (en) * | 2003-12-22 | 2005-07-07 | Wakunaga Pharmaceutical Co., Ltd. | Fat composition |
JP2008035714A (ja) * | 2006-08-01 | 2008-02-21 | Wakasa Seikatsu:Kk | 健康食品 |
JP2008239528A (ja) * | 2007-03-26 | 2008-10-09 | Lion Corp | 目及び脳機能改善剤 |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
JP5979816B2 (ja) | 2008-01-04 | 2016-08-31 | ネステク ソシエテ アノニム | 不飽和脂肪酸及び酸化窒素放出化合物を含む組成物、並びに認知機能及び関連の機能を高めるためのそれらの使用 |
EP2110027A1 (en) * | 2008-04-01 | 2009-10-21 | Nestec S.A. | Long-chain polyunsaturated fatty acids (LC-PUFA) in maternal nutrition during pregnancy and lactation |
US20090264520A1 (en) * | 2008-04-21 | 2009-10-22 | Asha Lipid Sciences, Inc. | Lipid-containing compositions and methods of use thereof |
US20130295171A1 (en) | 2009-07-23 | 2013-11-07 | U.S NUTRACEUTICALS, LLC d/b/a Valensa International | Krill oil and reacted astaxanthin composition and associated method |
CA2779334C (en) | 2009-10-30 | 2017-05-30 | Tharos Ltd. | Solvent-free process for obtaining phospholipids and neutral enriched krill oils |
IT1397386B1 (it) * | 2010-01-12 | 2013-01-10 | Indena Spa | Composizioni a base di estratti di andrographis paniculata combinati con estratti di ginkgo biloba complessati con fosfolipidi e loro uso. |
KR20110107615A (ko) * | 2010-03-25 | 2011-10-04 | 서울대학교산학협력단 | 크릴 오일을 유효 성분으로 포함하는 지질유제 및 그의 제조 방법 |
US9763897B2 (en) | 2010-04-30 | 2017-09-19 | U.S. Nutraceuticals, LLC | Therapeutic astaxanthin and phospholipid composition and associated method |
US8663704B2 (en) * | 2010-04-30 | 2014-03-04 | U.S. Nutraceuticals, LLC | Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans |
NZ709083A (en) * | 2012-12-24 | 2020-07-31 | Qualitas Health Inc | Eicosapentaenoic acid (epa) formulations |
US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
JP6614581B2 (ja) * | 2014-03-17 | 2019-12-04 | 三菱商事ライフサイエンス株式会社 | リン脂質型αリノレン酸含有組成物 |
KR101464129B1 (ko) * | 2014-04-02 | 2014-11-21 | 주식회사 천지양 | 홍삼추출물, 공액리놀레산 및 감마리놀렌산의 혼합물을 함유한 나노캡슐 |
CN106615227A (zh) * | 2016-11-25 | 2017-05-10 | 南通博泰美术图案设计有限公司 | 橄榄油 |
CN107343892A (zh) * | 2017-06-14 | 2017-11-14 | 芜湖福民生物药业股份有限公司 | 中药口服液及其制备方法 |
KR102206166B1 (ko) * | 2019-04-03 | 2021-01-21 | 동의대학교 산학협력단 | 흑임자 전처리용 조성물로 전처리된 흑임자 오일의 제조방법 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01290625A (ja) * | 1988-05-16 | 1989-11-22 | Nippon Oil & Fats Co Ltd | 脳機能向上剤 |
ES2033193B1 (es) * | 1990-10-30 | 1994-01-16 | Ganadera Union Ind Agro | Mezcla grasa para nutricion infantil y de adultos. |
JPH06237734A (ja) * | 1991-11-06 | 1994-08-30 | Sanwa Kagaku Kenkyusho Co Ltd | 機能後退性疾患用食品組成物 |
US5484611A (en) * | 1992-07-15 | 1996-01-16 | The Scottish Agricultural College | Method of producing a fatty acid |
JPH0717855A (ja) * | 1992-09-02 | 1995-01-20 | Maruha Corp | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品 |
FR2698269B1 (fr) * | 1992-11-24 | 1995-01-06 | Inst Nat Sante Rech Med | Nouveaux médicaments à base d'acides gras insaturés, utilisables notamment comme antiagrégants plaquettaires et/ou comme transporteurs privilégiés vers le cerveau. |
JP3011827B2 (ja) * | 1993-04-30 | 2000-02-21 | 勝造商事株式会社 | 脳細胞活性化製剤 |
JPH08245335A (ja) * | 1995-03-15 | 1996-09-24 | Itano Reitou Kk | 化粧料 |
JP2826808B2 (ja) * | 1995-07-14 | 1998-11-18 | カルピス株式会社 | 脳機能改善、学習能力増強および記憶力増強作用を有する機能性食品 |
JPH1029938A (ja) * | 1996-07-17 | 1998-02-03 | Maruha Corp | 虚血性眼疾患の予防および/または治療剤 |
JP4229297B2 (ja) * | 1998-11-02 | 2009-02-25 | 日本水産株式会社 | オキアミ乾燥粉粒体 |
KR100341109B1 (ko) * | 1999-03-10 | 2002-06-20 | 이인수 | 인식력 및 기억력 증강용 식이 조성물 |
JP2001002569A (ja) * | 1999-06-18 | 2001-01-09 | Itano Refrigerated Food Co Ltd | 記憶力改善組成物 |
US6964969B2 (en) * | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
US7704542B2 (en) * | 2001-09-12 | 2010-04-27 | Xanodyne Pharmaceuticals, Inc. | Vitamin/mineral compositions with DHA |
CA2549429A1 (en) * | 2003-12-22 | 2005-07-07 | Wakunaga Pharmaceutical Co., Ltd. | Fat composition |
-
2004
- 2004-12-21 CA CA002549429A patent/CA2549429A1/en not_active Abandoned
- 2004-12-21 JP JP2005516489A patent/JPWO2005061684A1/ja active Pending
- 2004-12-21 CN CNA2004800385954A patent/CN1898370A/zh active Pending
- 2004-12-21 KR KR1020067012289A patent/KR20060127865A/ko not_active Application Discontinuation
- 2004-12-21 EP EP04807408A patent/EP1698685A4/en not_active Withdrawn
- 2004-12-21 WO PCT/JP2004/019051 patent/WO2005061684A1/ja not_active Application Discontinuation
- 2004-12-21 US US10/582,940 patent/US20070122452A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103947770B (zh) * | 2014-05-16 | 2016-03-09 | 普洱联众生物资源开发有限公司 | 一种有利于视力的天然植物油 |
CN105412227A (zh) * | 2015-12-02 | 2016-03-23 | 北京世纪合辉医药科技股份有限公司 | 一种不饱和脂肪酸膳食补充剂及其制备方法 |
CN105962359A (zh) * | 2016-05-10 | 2016-09-28 | 中国农业科学院油料作物研究所 | 一种具有辅助改善记忆功能的组合物 |
CN110946099A (zh) * | 2019-12-13 | 2020-04-03 | 宁波大学 | 一种提高双壳贝类苗种繁育产量的方法 |
Also Published As
Publication number | Publication date |
---|---|
US20070122452A1 (en) | 2007-05-31 |
KR20060127865A (ko) | 2006-12-13 |
WO2005061684A1 (ja) | 2005-07-07 |
EP1698685A4 (en) | 2008-12-03 |
CA2549429A1 (en) | 2005-07-07 |
JPWO2005061684A1 (ja) | 2007-12-13 |
EP1698685A1 (en) | 2006-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1898370A (zh) | 油脂组合物 | |
KR101156789B1 (ko) | 젤라틴 피막용 조성물, 젤라틴 피막, 및 이를 이용한 캡슐제 | |
US20050106272A1 (en) | Co-beadlet of dha and rosemary and methods of use | |
CN102215839B (zh) | 用于人工喂养重病的重症特护患者的脂肪乳剂 | |
CN1927050A (zh) | Dha微胶囊食品添加剂、dha软胶囊保健品及其应用 | |
JP2012508791A5 (zh) | ||
JP6896417B2 (ja) | クリルオイルと魚油とシソ油とを含有する組成物 | |
JP2007504197A (ja) | ホスファチジルセリン塩基の生理学的活性組成物 | |
JP2012102070A (ja) | クリル由来のリン脂質を用いて、アスタキサンチンとdah−及び/又はepa−結合したホスファチジルセリンとを含有する組成物を製造する方法、ならびにこの方法により製造された組成物 | |
JP4913340B2 (ja) | カプセル剤 | |
JPH0336493B2 (zh) | ||
JP2005206789A (ja) | 新規油脂組成物 | |
US20190216762A1 (en) | Vegetarian composition containing unsaturated fatty acids | |
CN107625127B (zh) | 南极磷虾油和泛醌的协同抗疲劳组合物、胶囊及制备方法 | |
JP2017002015A (ja) | サプリメント及びその製造方法 | |
JP3623944B2 (ja) | ホスファチジルセリン高含有組成物 | |
Jafari et al. | Plant Oils Rich in Essential Fatty Acids | |
JP4969989B2 (ja) | リン脂質組成物およびこれを含有する食品組成物、医薬品組成物、並びにその製造方法 | |
CN1708290A (zh) | 含有稳定胆碱的剂型及其制备方法 | |
JP4594489B2 (ja) | 特異的殺癌細胞剤及びこれを配合してなる組成物 | |
CN1445349A (zh) | 添加共轭亚油酸的油脂及减缓不饱和脂肪酸氧化、促进其吸收的方法 | |
JP7163354B2 (ja) | クリルオイルと魚油とシソ油とを含有する組成物 | |
TWI661780B (zh) | 含不飽和脂肪酸的素食組合物 | |
JPH01290625A (ja) | 脳機能向上剤 | |
JP5221114B2 (ja) | ソフトカプセル剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1096990 Country of ref document: HK |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20070117 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1096990 Country of ref document: HK |